Recent Pfizer Press Releases

  • 9/21/17 10:00 am EDT

    Pfizer, NNPA, and Howard University Collaborate to Improve Public Education and Awareness

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE), the National Newspaper Publishers Association (NNPA), and scholars from Howard University today announced results from a new national poll designed to deepen understanding and gauge perceptions around sickle cell disease (SCD) among African Americans. The poll, which included responses from adults in the US who self-identified as African American, revealed that while the majority of respondents were familiar with SCD andmore...
  • 9/20/17 9:10 am EDT

    Lawsuit Claims Johnson & Johnson Engaged in Unlawful Conduct to Stifle Competition From Inflectra

    NEW YORK--(BUSINESS WIRE)--To ensure patients and providers have access to important, lower cost biosimilar medicines, Pfizer (NYSE:PFE) today filed suit in the U.S. District Court for the Eastern District of Pennsylvania against Johnson & Johnson (J&J). The suit alleges that J&J’s exclusionary contracts and other anticompetitive practices have denied U.S. patients access to therapeutic options and undermined the benefits of robust pricemore...
  • 9/19/17 1:15 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drug Advisory Committee (ODAC) voted 6 in favor and 6 against the benefit-risk profile for SUTENT® (sunitinib) as adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma (RCC) after nephrectomy (surgical removal of the cancer-containing kidney). The role of the Advisory Committee is to provide recommendations to the FDAmore...
  • 9/19/17 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 31, 2017. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2017 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizermore...
  • 9/14/17 5:00 am EDT
    • Enzalutamide is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in this patient population in a randomized, controlled clinical trial
    NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that the Phase 3 PROSPER trial evaluating XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS). The preliminary safety analysis of the PROSPERmore...
  • 9/11/17 7:00 am EDT

    Longest Ever Follow-up Reported for Patients with Advanced ALK-positive NSCLC

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced final overall survival (OS) data from the PROFILE 1014 trial examining XALKORI® (crizotinib) in previously untreated patients with ALK-positive advanced non-small cell lung cancer(NSCLC). After a median follow-up of 46 months, the median OS for patients randomized to XALKORI was not reached (95% CI: 45.8 months, not reached) and was 47.5 months for patients randomized to chemotherapy (95% CI: 32.2 months,more...
  • 9/10/17 3:15 am EDT
    • Data from the REFLECTIONS B327-02 study demonstrates equivalence in objective response rate (ORR) for patients with HER2-positive metastatic breast cancer
    • Marketing applications accepted for review by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced positive findings from REFLECTIONS B327-02 (n=707), a pivotal Phase 3 randomized, double-blind comparative safety and efficacy study of the company’s investigational trastuzumab biosimilar (PF-05280014) versus Herceptin®1 (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid. Positive data from a supplemental study, REFLECTIONS B327-04 (n=226), were also presented at themore...
  • 9/6/17 10:00 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Executive Vice President, Business Operations, and Chief Financial Officer, at the Morgan Stanley 15th Annual Global Healthcare Conference on Wednesday, September 13, 2017 at 9:55 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and pre-registeringmore...
  • 9/1/17 11:38 am EDT

    Only approved antibody-drug conjugate for newly diagnosed and relapsed or refractory CD33-positive acute myeloid leukemia

    Reintroduction of MYLOTARG supported by continued research by the AML community demonstrating favorable risk:benefit profile

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration approved MYLOTARG™ (gemtuzumab ozogamicin) for adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), and adults and children 2 years and older with relapsed or refractory CD33-positive AML.1 MYLOTARG is the first therapy with an indication that includes pediatric AML. It is also the only AML therapy that targets CD33, an antigen expressed on AMLmore...
  • 8/31/17 8:54 am EDT

    Analysis Provides Longest Evaluation of Any Medication for Hereditary Transthyretin Amyloid Polyneuropathy (TTR-FAP), a Neurodegenerative Disease

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced the publication of a new interim analysis of long-term data from four studies indicating that treatment with tafamidis is associated with delay in disease progression in patients with hereditary transthyretin amyloid polyneuropathy (TTR-FAP) and was well tolerated, with no unexpected side effects. The publication, “Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretinmore...